Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.270
+0.001 (0.37%)
Apr 29, 2026, 11:03 AM GMT
77.05%
Market Cap 18.31M
Revenue (ttm) n/a
Net Income (ttm) -2.59M
Shares Out 6.81B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,659,150
Average Volume 36,780,175
Open 0.265
Previous Close 0.269
Day's Range 0.260 - 0.290
52-Week Range 0.125 - 0.400
Beta 1.27
RSI 50.43
Earnings Date Apr 30, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Sector Industrials
Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.